The impact of provider recommendation on human papillomavirus vaccine and other adolescent vaccines. Issue 4 (3rd April 2021)

• Record Type: Journal Article
• Authors: Caldwell, Alexandria C.; Madden, Christi A.; Thompson, David M.; Garbe, M. Connor; Roberts, James R.; Jacobson, Robert M.; Darden, Paul M.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 4(2021)
• Page Start: 1059
• Page End: 1067
• Publication Date: 2021-04-03
• Subjects: Provider recommendation -- vaccine coverage -- adolescents; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2020.1817713
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: This study explored the association between provider recommendation and adolescent vaccine coverage. We analyzed data from the 2008 to 2018 National Immunization Survey-Teen including coverage with one dose of quadrivalent meningococcal conjugate vaccine (MenACWY), Tetanus-diphtheria-acellular pertussis vaccine (Tdap), and one and three doses of Human papillomavirus (HPV) vaccine. We compared vaccine coverage between those who recalled a provider recommendation and those who did not. Among those who received a provider recommendation for MenACWY, coverage trended from 67.8% (2008) to 88.1% (2013), contrasted to those who did not, trending from 30.9% to 73.1%. Among those with a provider recommendation for Tdap, coverage trended from 47.6% to 89.7%, contrasted to those who did not, trending from 35.6% to 82.2%. Among females with a provider recommendation for HPV vaccine, receipt of initial dose of HPV vaccine trended from 57.5% (2008) to 74.3% (2018), contrasted to those who did not, trending from 18.1% to 49.8%, and among males, trended from 17.2% (2010) to 75.1% (2018) for those with a provider recommendation, compared to 0.5% to 44.7% for those without. In 2013, coverage difference by provider recommendation was 26.0% among females for one dose of HPV vaccine and 21.9% for three doses, and among males was 44.8% and 20.8%, respectively, while it was lower at 15% for MenACWY and 7.6% for Tdap. For each vaccine, coverage was higher with a provider recommendation; the largest difference was noted for HPV vaccine. This finding verifies for providers the importance of their recommendation, especially for the HPV vaccine.